Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Basal Insulin (Glargine)

Placebo

Core clinician-reference fields are available or not applicable.

Participants received GLP-1 (Liraglutide) in combination with metformin and sulfonylurea.

GLP-1 (Liraglutide)

We considered three treatment arms: GLP-1 (Liraglutide), basal insulin (glargine), and placebo. After training, virtual trials were conducted by sampling 232 virtual patients per arm (according to the LEAD-5 inclusion criteria) and predicting post-treatment outcomes.

Participants received basal insulin (glargine) in combination with metformin and sulfonylurea.

We considered three treatment arms: GLP-1 (Liraglutide), basal insulin (glargine), and placebo.

Participants received placebo in combination with metformin and sulfonylurea.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

AI Emulation Shows GLP-1 Improves HbA1c in Type 2 Diabetes

Reference Liraglutide

T2DM patients with obesity receiving Liraglutide Biosimilar.

Liraglutide Biosimilar

Group A – Intervention arm: Liraglutide Biosimilar in T2DM patients with obesity

T2DM patients with obesity receiving Reference Liraglutide.

Group B – Control arm: Reference Liraglutide in T2DM patients with obesity

Liraglutide biosimilar shows significant weight reduction in T2DM patients

Source evidence could not be resolved sufficiently for this field.

Not extracted from the authoritative source.

Clinician-reference record is usable with limitations in: design, risk_of_bias.

Participants received liraglutide as a once-daily subcutaneous injection.

Liraglutide

Participants were randomized 2:1 to receive a once-daily subcutaneous injection of liraglutide (up to 1.8 mg/day) or placebo.

Participants received a placebo injection.

Authoritative quality diagnostic: source evidence unresolved.

Liraglutide × HbA1c

Available supporting studies

AI Emulation Shows GLP-1 Improves HbA1c in Type 2 Diabetes

Liraglutide biosimilar shows significant weight reduction in T2DM patients

Liraglutide improves glycaemic control in adults with T2D